Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Steven Azuma

Cardiovascular Disease Honolulu, HI Medical Doctor

NPI 1518966233 CMS profile 68895

321 N Kuakini St, Ste 709, Honolulu, HI 96817

Open in the dashboard

General payments

$2,989

153 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Steven Azuma of Honolulu, HI is reported in the CMS Open Payments database as having received $2,989 across 153 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 58th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $221 5
2022 General $520 25
2021 General $1,126 72
2020 General $795 37
2019 General $327 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Steven Azuma
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Steven Azuma were reported at $0. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Steven Azuma Cardiovascular Disease median Middle half National median
2019 $327 $450 $127–$1,392 $163
2020 $795 $242 $77–$751 $114
2021 $1,126 $335 $101–$1,037 $132
2022 $520 $395 $121–$1,211 $149
2023 $221 $443 $136–$1,283 $160
2024 $0 $450 $136–$1,323 $164
2025 $0 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Amarin Pharma Inc. $804 63 payments
  2. Boston Scientific Corporation $662 15 payments
  3. E.R. Squibb & Sons, L.L.C. $374 22 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $267 12 payments
  5. AstraZeneca Pharmaceuticals LP $266 15 payments
  6. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $180 10 payments
  7. Novartis Pharmaceuticals Corporation $142 8 payments
  8. Abbott Laboratories $129 5 payments
  9. Bayer HealthCare Pharmaceuticals Inc. $125 1 payment
  10. Amgen Inc. $22 1 payment
  11. Other $18 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $2,864 152 payments
  2. Consulting Fee $125 1 payment
Products named General payments · program years 2019–2023
  1. Vascepa $783 62 payments
  2. ELIQUIS $348 21 payments
  3. JARDIANCE $267 12 payments
  4. BRILINTA $266 15 payments
  5. SYNERGY Synergy_Ic $245 3 payments
  6. LifeVest $180 10 payments
  7. ENTRESTO $142 8 payments
  8. Adempas $125 1 payment
  9. Synergy Stents $115 2 payments
  10. LUX-DX $98 2 payments
  11. Other $421 17 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 4 billing codes

Paid by Medicare

$10,292

Medicare's payments for the services billed

Medicare patients

767

Average age 79

Services billed

1,081

412 women, 355 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 50%
Arthritis 48%
Diabetes 44%
Ischemic heart disease 35%
Heart failure 28%
Atrial fibrillation 28%
Osteoporosis 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

153 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Hawaii

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record